Your browser doesn't support javascript.
loading
Effects of unplanned treatment interruptions on HIV treatment failure - results from TAHOD.
Jiamsakul, Awachana; Kerr, Stephen J; Ng, Oon Tek; Lee, Man Po; Chaiwarith, Romanee; Yunihastuti, Evy; Van Nguyen, Kinh; Pham, Thuy Thanh; Kiertiburanakul, Sasisopin; Ditangco, Rossana; Saphonn, Vonthanak; Sim, Benedict L H; Merati, Tuti Parwati; Wong, Wingwai; Kantipong, Pacharee; Zhang, Fujie; Choi, Jun Yong; Pujari, Sanjay; Kamarulzaman, Adeeba; Oka, Shinichi; Mustafa, Mahiran; Ratanasuwan, Winai; Petersen, Boondarika; Law, Matthew; Kumarasamy, Nagalingeswaran.
Afiliação
  • Jiamsakul A; The Kirby Institute, UNSW Australia, Sydney, Australia.
  • Kerr SJ; The Kirby Institute, UNSW Australia, Sydney, Australia.
  • Ng OT; HIV-NAT, The Thai Red Cross AIDS Research Centre, Bangkok, Thailand.
  • Lee MP; Department of Global Health, Academic Medical Center, University of Amsterdame, Amsterdam Institute for Global Health and Development, Amsterdam, The Netherlands.
  • Chaiwarith R; Department of Infectious Diseases, Tan Tock Seng Hospital, Singapore City, Singapore.
  • Yunihastuti E; Queen Elizabeth Hospital, Hong Kong, China.
  • Van Nguyen K; Research Institute for Health Sciences, Chiang Mai University, Chiang Mai, Thailand.
  • Pham TT; Working Group on AIDS, Faculty of Medicine, University of Indonesia/Cipto Mangunkusumo Hospital, Jakarta, Indonesia.
  • Kiertiburanakul S; National Hospital for Tropical Diseases, Hanoi, Vietnam.
  • Ditangco R; Bach Mai Hospital, Hanoi, Vietnam.
  • Saphonn V; Faculty of Medicine Ramathibodi Hospital, Mahidol University, Bangkok, Thailand.
  • Sim BL; Research Institute for Tropical Medicine, Manila, Philippines.
  • Merati TP; National Center for HIV/AIDS, Dermatology & STDs and University of Health Sciences, Phnom Penh, Cambodia.
  • Wong W; Hospital Sungai Buloh, Sungai Buloh, Malaysia.
  • Kantipong P; Faculty of Medicine Udayana University & Sanglah Hospital, Bali, Indonesia.
  • Zhang F; Taipei Veterans General Hospital, Taipei, Taiwan.
  • Choi JY; Chiangrai Prachanukroh Hospital, Chiang Rai, Thailand.
  • Pujari S; Beijing Ditan Hospital, Capital Medical University, Beijing, China.
  • Kamarulzaman A; Division of Infectious Diseases, Department of Internal Medicine, Yonsei University College of Medicine, Seoul, South Korea.
  • Oka S; Institute of Infectious Diseases, Pune, India.
  • Mustafa M; University of Malaya Medical Centre, Kuala Lumpur, Malaysia.
  • Ratanasuwan W; National Center for Global Health and Medicine, Tokyo, Japan.
  • Petersen B; Hospital Raja Perempuan Zainab II, Kota Bharu, Malaysia.
  • Law M; Faculty of Medicine, Siriraj Hospital, Mahidol University, Bangkok, Thailand.
  • Kumarasamy N; TREAT Asia, amfAR - The Foundation for AIDS Research, Bangkok, Thailand.
Trop Med Int Health ; 21(5): 662-74, 2016 May.
Article em En | MEDLINE | ID: mdl-26950901
ABSTRACT

OBJECTIVES:

Treatment interruptions (TIs) of combination antiretroviral therapy (cART) are known to lead to unfavourable treatment outcomes but do still occur in resource-limited settings. We investigated the effects of TI associated with adverse events (AEs) and non-AE-related reasons, including their durations, on treatment failure after cART resumption in HIV-infected individuals in Asia.

METHODS:

Patients initiating cART between 2006 and 2013 were included. TI was defined as stopping cART for >1 day. Treatment failure was defined as confirmed virological, immunological or clinical failure. Time to treatment failure during cART was analysed using Cox regression, not including periods off treatment. Covariables with P < 0.10 in univariable analyses were included in multivariable analyses, where P < 0.05 was considered statistically significant.

RESULTS:

Of 4549 patients from 13 countries in Asia, 3176 (69.8%) were male and the median age was 34 years. A total of 111 (2.4%) had TIs due to AEs and 135 (3.0%) had TIs for other reasons. Median interruption times were 22 days for AE and 148 days for non-AE TIs. In multivariable analyses, interruptions >30 days were associated with failure (31-180 days HR = 2.66, 95%CI (1.70-4.16); 181-365 days HR = 6.22, 95%CI (3.26-11.86); and >365 days HR = 9.10, 95% CI (4.27-19.38), all P < 0.001, compared to 0-14 days). Reasons for previous TI were not statistically significant (P = 0.158).

CONCLUSIONS:

Duration of interruptions of more than 30 days was the key factor associated with large increases in subsequent risk of treatment failure. If TI is unavoidable, its duration should be minimised to reduce the risk of failure after treatment resumption.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Infecções por HIV / Fármacos Anti-HIV / Adesão à Medicação Tipo de estudo: Etiology_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Limite: Adult / Female / Humans / Male / Middle aged País/Região como assunto: Asia Idioma: En Ano de publicação: 2016 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Infecções por HIV / Fármacos Anti-HIV / Adesão à Medicação Tipo de estudo: Etiology_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Limite: Adult / Female / Humans / Male / Middle aged País/Região como assunto: Asia Idioma: En Ano de publicação: 2016 Tipo de documento: Article